Links to Data sources

Sr. No Display Name Type Country Last Updated
1 PHARMO Database Network Data Source Netherlands 12/01/2018

Links to Studies

Status Official Title Lead Investigator Last Updated
Finalised Dulaglutide Modified-Prescription-Event Monitoring Study and network database study: a multi-database collaborative research program of observational studies to monitor the utilisation and safety of dulaglutide in the EU Professor Saad Shakir 11/11/2021
Finalised A pharmacoepidemiological study of Rivaroxaban use and potential adverse outcomes in routine clinical pratice in the Netherlands Dr Ron Herings 23/09/2021
Finalised Intravenous Iron Postauthorisation Safety Study (PASS): Evaluation of the Risk of Severe Hypersensitivity Reactions Mrs Lia Gutierrez 08/09/2021
Finalised Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines Professor Miriam Sturkenboom 26/08/2021
Finalised Impact of EU label changes for hydroxyzine products: post-referral prescribing trends Professor Thomas MacDonald 06/01/2021
Finalised Impact of EU label changes for systemic diclofenac products: post-referral prescribing trends Professor Thomas MacDonald 16/02/2020
Finalised Drug Utilisation Study for Olodaterol Dr Alicia Gilsenan 21/01/2020
Finalised Adherence, persistence and switching patterns – once- and twice-daily direct oral anticoagulants Dr Ron Herings 19/12/2019
Finalised Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus, Pimecrolimus, and Corticosteroids Dr Alejandro Arana 22/11/2019
Finalised Drug Utilization Study on Diane®-35 (and generics) in European healthcare databases Dr CTP Team / Ref: "ENCePP"/ Bayer Pharma AG Bayer HealthCare AG 26/08/2019
Finalised Drug utilization study of mirabegron (Betmiga®) using real-world healthcare databases from the Netherlands, Spain, United Kingdom and Finland Dr Ron Herings 02/05/2019
Finalised Malignancies in Multiple Sclerosis: multi-country cohort database studies (feasibility study) Dr Patrick Blin 01/04/2019
Finalised A PHARMO Study on the Utilization of Pioglitazone in Clinical Practice in The Netherlands with Regard to Diabetic Treatment Regimen and Co-morbidities Dr Ron Herings 11/03/2019
Finalised A multinational active safety surveillance study of crizotinib in Europe Professor Henrik Toft Sørensen 18/07/2018
Finalised Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus, Pimecrolimus, and Corticosteroids Dr Jordi Castellsague 15/05/2018
Finalised Identification of type 2 diabetes cases in a set of databases participating to the EMIF project Dr Roberto Giuseppe 11/12/2017
Finalised Safety Evaluation of Adverse Reactions in Diabetes - Comparative studies Professor Miriam Sturkenboom 25/08/2017
Finalised Safety Evaluation of Adverse Reactions in Diabetes - Drug utilisation studies Professor Miriam Sturkenboom 25/08/2017
Finalised Arrhythmogenic Potential of Drugs Professor Miriam Sturkenboom 25/08/2017
Finalised Patterns and Determinants of Use of Oral Contraceptives in the European Union Professor Miriam Sturkenboom 25/08/2017
Finalised Risk of cardiac valve disorders associated with the use of biphosphonates Professor Miriam Sturkenboom 25/08/2017
Finalised Evaluation of the Use of Nepafenac in Selected European Populations Dr Alejandro Arana Navarro 25/07/2017
Finalised Pan European Multi-Database Bladder Cancer Risk Characterisation Study Dr Pasi Korhonen 30/05/2017
Finalised POST-APPROVAL SAFETY STUDY (PASS) OF THE UTILIZATION PATTERN OF APIXABAN IN THE NETHERLANDS Dr Stephen Schachterle 28/07/2016
Finalised Real-world effectiveness of extrafine vesrus standard particle inhaled corticosteroids: A comparative effectiveness analysis of extrafine (EF) hydrofluoroalkane beclometasone (HFA-BDP) and Ciclesonide versus commonly prescribed standard particle inhaled corticosteroids for patients prescribed asthma therapy in The Netherlands. Dr Cristiana Miglio 21/01/2015
Ongoing Non-interventional post-authorization multi-database safety study to characterize the risk of angioedema and other specific safety events of interest in association with use of Entresto® (sacubitril/valsartan) in adult patients with heart failure Ms Novartis Clinical Disclosure Officer 05/05/2021
Ongoing Non-interventional post-authorization multi-database safety study to assess the risk of myotoxicity, hepatotoxicity and acute pancreatitis in statin-exposed heart failure patients with or without concomitant use of sacubitril/valsartan (Entresto®) Ms Novartis Clinical Disclosure Office 05/05/2021
Ongoing ACCESS template protocol for safety of COVID-19 vaccines Professor Miriam Sturkenboom 19/02/2021
Ongoing A Retrospective Cohort Study to Assess Drug Utilisation and Long-Term Safety of Galcanezumab in European Patients in the Course of Routine Clinical Care Dr Krista Schroeder 30/07/2020
Ongoing Estimating prevalence and incidence of acute myocardial infarction in a set of heterogeneous sources of observational health data collaborating in the EMIF Platform Dr Roberto Giuseppe 14/02/2019
Ongoing Comparison of the Risk of Cancer Between Patients With Type 2 Diabetes Exposed to Dapagliflozin and Those Exposed to Other Antidiabetic Treatments Ms Lia Gutierrez 03/07/2017
Planned A post-authorisation/post-marketing observational study to evaluate the association between exposure to AZD1222 and safety concerns using existing secondary health data sources (COVID-19) Dr Cristina Rebordosa 23/11/2021
Planned Cohort monitoring of Adverse Events of Special Interest and COVID-19 diagnoses prior to and after COVID-19 vaccination Professor Miriam Sturkenboom 23/11/2021
Planned The BRodalumab Assessment of Hazards: A Multinational Safety (BRAHMS) study in electronic healthcare databases Professor Jesper Hallas 05/10/2021
Planned Rapid Safety Assessment of SARS-CoV-2 vaccines in EU Member States using electronic health care datasources Professor Miriam Sturkenboom 26/08/2021
Planned Impact of EU label changes and revised pregnancy prevention programme for medicinal products containing valproate: utilisation and prescribing trends Professor Olaf Klungel 01/08/2020
Planned Impact of EU label changes and revised pregnancy prevention programme for oral retinoid containing medicinal products: utilization and prescribing trends Dr Miriam Sturkenboom 19/09/2019